AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01361555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-820836
Description: Tablet, Oral, 2.0 mg, Once daily, 54 weeks
Study NCT01792700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole
Study NCT01792700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tripotassium dicitrate bismuthate
Study NCT01792700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metronidazole
Study NCT01792700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tetracycline
Study NCT01792700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Study NCT01792700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin
Study NCT00317473 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMP1/AS02A Malaria vaccine
Description: Subjects vaccinated with FMP1/AS02 vaccine
Study NCT00317473 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Imovax Rabies vaccine
Description: Subjects vaccinated on corresponding FMP1/AS02A vaccination days
Study NCT05772741 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biological sample collection
Description: Collection of biological samples
Study NCT04265196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive behavioral group therapy
Description: A unique protocol that includes cognitive-behavioral psychological therapy with emphasis on coping with pain
Study NCT04265196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-based group therapy
Description: Unique protocol that includes mindfulness-based psychological therapy with emphasis on coping with pain
Study NCT01590264 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Bimodal rTMS
Description: High frequency (10 Hz) at 110% of the motor threshold TMS delivered over the left dorsolateral prefrontal cortex, subsequently, a low frequency TMS (1 Hz) at 110% motor threshold will be delivered over 31 minutes over the TPJ area, according to the protocol below.~DLPFC Stimulation Frequency 10 Hz Intensity 110% of motor threshold On 5 seconds Off 15 seconds Total Trains 80 per session Total pulses session 4000/session Duration session 26.6 minutes Total pulses (study) 40000~TPJ Stimulation Frequency 1 Hz Intensity 110% of motor threshold On 900 seconds Off 60 seconds Total Trains 2 per session Total Pulses session 1800 Duration session 31 minutes Total Pulses study 18000
Study NCT01329978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir (SOF) administered as a 400 mg tablet orally once daily
Study NCT03524053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise induced bronchoconstriction
Description: Participants will exercise whilst inhaling dry-air, this is known to exacerbate the bronchoconstrictive response.
Study NCT01329978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study NCT01329978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG
Description: Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
Study NCT01233596 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Canalicular intubation
Description: Intubation through the inferior canaliculus performed under general anaeshesia. The tubes were removed 3-4 months after the tube placement.
Study NCT01204099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Study NCT01204099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT01204099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PX-866
Study NCT01031719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adjuvanted A(H1N1) influenza vaccine
Description: 7.5 ug of HA antigen; adjuvanted; monovalent
Study NCT01031719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: non-adjuvanted A(H1N1) influenza vaccine
Description: 15ug of HA antigen, non-adjuvanted; trivalent
Study NCT01031719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: non-adjuvanted A(H1N1) influenza vaccine
Description: 15 mcg of antigen; non-adjuvanted; trivalent
Study NCT01222845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test meal
Description: Porridge made from rolled, or pinhead oats providing 50 g of carbohydrate
Study NCT03400618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate carbohydrate diet
Description: 30 E % carbohydrates included in the diet
Study NCT03400618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Higher carbohydrate diet
Description: 50 E % carbohydrates included in the diet
Study NCT02922530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Plasticity-based Adaptive Cognitive Training
Study NCT02922530 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available computerized training
Study NCT03557970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edicotinib
Description: Given PO
Study NCT03557970 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Correlative studies
Study NCT04562922 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lifemel
Study NCT00701285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pitavastatin
Description: pitavastatin 4mg once daily
Study NCT00701285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pravastatin
Description: pravastatin 10mg once daily
Study NCT03524053 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inhibited EIB
Description: Participants will perform the exercise-test whilst inhaling warm-humid air. This is known to inhibit the EIB response and will provide a direct comparison group for the EIB condition.
Study NCT01477554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRONTO training
Description: PRONTO is an intervention consisting of two training modules for medical professionals. Module 1 is delivered over 2-3 days, takes place in the hospital, and consists of high-fidelity, low-tech simulations. The curriculum employs elements of the Team STEPPS program to strengthen teamwork and leadership skills, and the use of effective communication techniques. The activities and simulations have clear objectives and use evidenced-based medical concepts. Module 2, the follow-up training, uses the same teaching methodology as Module 1 to reinforce teamwork, communication, and emergency response skills, and incorporates new topics such as preeclampsia /eclampsia, shoulder dystocia and pelvic presentation.
Study NCT02641860 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Mesenchymal progenitor cells
Description: Biological: Allogenic Adipose tissue-derived mesenchymal progentior cells administrated for intra-articular use
Study NCT00875927 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no scraping microcapsules
Description: 1, 4 grams isomalt candy containing no scraping microcapsules
Study NCT00875927 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: scraping microcapsules containing inert TCP microcapsules
Description: 1, 4 grams isomalt candy containing 2% inert TCP scraping microcapsules
Study NCT00875927 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: scraping microcapsules containing Propolis
Description: 1, 4 grams, isomalt candy containing 2% Propolis scraping microcapsules
Study NCT00875927 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: scraping microcapsules containing and Zinc
Description: 1, 4 grams, isomalt candy containing 2% Zinc scraping microcapsules
Study NCT00875927 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: scraping microcapsules containing Propolis and Zinc
Description: 1, 4 grams, isomalt candy containing 2% Propolis and Zinc scraping microcapsules
Study NCT01058031 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR
Description: Mindfulness Based Stress Reduction
Study NCT00860730 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aortic valve replacement with Perceval aortic heart valve
Description: Replacement of diseased or malfunctioning native aortic valve via traditional surgery (open chest) with the Perceval S prosthesis
Study NCT00724841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obatoclax Mesylate
Description: Obatoclax Mesylate (GMX1777) at various doses in combination with temozolomide
Study NCT00724841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Study NCT04050046 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: tDCS is a neuromodulatory technique that delivers a small electric current (about the equivalent of a 9V battery) to the head. A fixed current between 1 and 2 mA is typically applied. tDCS works by applying a positive (anodal) or negative (cathodal) current via electrodes to an area, facilitating the depolarization or hyperpolarization of neurons, respectively.
Study NCT04050046 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: tDCS is a neuromodulatory technique that delivers a small electric current (about the equivalent of a 9V battery) to the head. A fixed current between 1 and 2 mA is typically applied. tDCS works by applying a positive (anodal) or negative (cathodal) current via electrodes to an area, facilitating the depolarization or hyperpolarization of neurons, respectively.
Study NCT04050046 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer-based cognitive therapy (CBCT)
Description: Repetitive, drill-like training usually presented in the form of a game that targets a specific cognitive construct.
Study NCT04050046 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Computer-based cognitive therapy (CBCT)
Description: Repetitive, drill-like training usually presented in the form of a game that targets a specific cognitive construct.
Study NCT02893709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Oral administration of omeprazole at therapeutic dose (20 mg daily) for a duration of 7 days
Study NCT01377584 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couple-oriented intervention
Description: The first session will occur before the patient receives his/her CPAP and will last approximately 2 hours. This session will provide the couple with education on sleep apnea and CPAP and information on different types of PAP therapy and cleaning procedures, explore patient's concerns about starting CPAP treatment, and provide a goal setting exercise. The second face to face session will occur one week after the patient receives his/her CPAP and will last approximately one and a half hours. The second session will provide the couple with information on CPAP usage and pre- and post-treatment AHI, explore barriers to CPAP use and benefits of CPAP use, and provide a goal setting exercise. The individual telephone follow-up sessions will occur two weeks after the patient has received his/her CPAP and will last approximately 20 minutes. This session will review CPAP usage and explore barriers and facilitators of CPAP use.
Study NCT01377584 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-oriented intervention
Description: The first session will occur before the patient receives his/her CPAP and will last approximately one and a half hours. This session will provide the patient with education on sleep apnea and CPAP and information on different types of PAP therapy and cleaning procedures, explore patient's concerns about starting CPAP treatment, and provide a goal setting exercise. The second face to face session will occur one week after the patient receives his/her CPAP and will last approximately 45 minutes. The second session will provide information on CPAP usage and pre- and post-treatment AHI, explore barriers to CPAP use and benefits of CPAP use, and provide a goal setting exercise. The telephone follow-up session will occur two weeks after the patient has received his/her CPAP and will last approximately 20 minutes. This session will review CPAP usage and explore barriers and facilitators of CPAP use.
Study NCT01377584 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous positive airway pressure (CPAP)
Description: CPAP is treatment for obstructive sleep apnea. CPAP therapy keeps the airway open during the night by providing a stream of air through a mask that is worn while sleeping.
Study NCT01377584 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Description: CPAP is treatment for obstructive sleep apnea. CPAP therapy keeps the airway open during the night by providing a stream of air through a mask that is worn while sleeping.
Study NCT01377584 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: No intervention will be received.
Study NCT03494270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvamibe
Description: Rosuvastatin 10mg/Ezetimibe 10mg
Study NCT03494270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monorova
Description: Rosuvastatin 20mg
Study NCT01766453 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Exercise
Description: Aerobic exercise with a progressive increase in intensity over 12 weeks.
Study NCT01766453 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bhangra dance exercise
Description: Bhangra Dance classes taught by an instructor.
Study NCT00828971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelox (Moxifloxacin, BAY12-8039)
Description: Sequential IV/PO moxifloxacin 400/400 mg every 24 hours, for 7 to 21 days.
Study NCT00828971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicilline/clavulanic
Description: IV Amoxicilline/clavulanic acid 2000/200 mg TID followed by PO amoxicilline/clavulanate 875/125 mg TID for a total of 7 to 21 days
Study NCT02579200 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: POWERbreathe®KHA (IMT group)
Description: 2 training sessions/day consisting of 30 breaths (\~50% maximal inspiratory pressure; Pi,max), 7 days/week (once/week supervised at research center), for 8 weeks using an electronic tapered flow resistive loading (TFRL) device (POWERbreathe®KH2, HaB International Ltd., Southam, UK). Measurements of PImax will be performed every week and training loads will be increased continuously to maintain the actual \~50% Pimax values.
Study NCT02579200 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: POWERbreathe®KH2 (sham group)
Description: 2 training sessions/day of 30 breaths at an inspiratory load of no more than 10% of their initial Pi,max (POWERbreathe®KH2, HaB International Ltd., Southam, UK). This training load will not be changed during the entire study period.
Study NCT03324490 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Spinal Anesthesia
Description: Spinal anesthesia will be performed for patients of the TSA group at the T7-T8 intervertebral space, using a 27 G pencil point needle with an introducer (Braun Melsungen, Melsungen, Germany).~When correct placement is confirmed by the free flow of clear CSF, 1.5 ml of hyperbaric Bupivacaine 0.5% (7.5 mg) in addition to 0.5 ml Fentanyl (25 μg) \& 5 μg dexmedetomidine will be injected.
Study NCT03324490 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Epidural Anesthesia
Description: Epidural anesthesia will be performed for patients of the TEA group at the T7-T8 intervertebral space, using the Prefix Custom Epidural Anesthesia Tray with an 18 G Tuohy epidural needle \& a 20 G epidural catheter.~Patients will initially receive 5-10 ml of a mixed preparation of 0.5% isobaric Bupivacaine with 2 μg Fentanyl per ml volume as a bolus dose via the epidural catheter, this will be followed by a continuous infusion of 5-10 ml/hr started 1 hour after the bolus dose \& continued throughout the procedure.
Study NCT03324490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.5% (hyperbaric)
Description: Neuro-axially injected
Study NCT03324490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.5% (isobaric)
Description: Neuro-axially injected
Study NCT03324490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Neuro-axially injected
Study NCT03324490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Neuro-axially injected
Study NCT00959608 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Think Health! program
Description: Brief 10-15 minute counseling with Primary Care Provider for weight management, Participant binder with eating, physical activity and stress management educational materials, adapted from the Diabetes Prevention Program (DPP)(Knowler et al, 2002; DPP Research Group, 2002), physical activity resource guide, and telephonic health related messages (year 2).
Study NCT00959608 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Think Health! program
Description: Brief 10-15 minute counseling with Primary Care Provider for weight management, Participant binder with eating, physical activity and stress management educational materials, adapted from the Diabetes Prevention Program (DPP)(Knowler et al, 2002; DPP Research Group, 2002), physical activity resource guide, and telephonic health related messages (year 2).
Study NCT00959608 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic Plus program
Description: 15 minute counseling sessions with lifestyle coach, in addition to the Basic Think Health! program intervention.
Study NCT00466063 — intervention group
Intervention type: DRUG
Intervention: Deferasirox
Study NCT04228263 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hydroxychloroquine
Description: 400mg
Study NCT04228263 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Folic Acid
Description: 5 mg
Study NCT04228263 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Low-dose aspirin
Description: 75 mg
Study NCT01784991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: 1mg of Hydromorphone at timepoint 0 and 1 mg of hydromorphone at 15 min timepoint.
Study NCT01784991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual care group
Description: Patient will have pain treated at timepoint 0 as per usual care based on physician discretion. At 15 min timepoint, patients will be asked for pain level, and then subsequently treated as per physician discretion.
Study NCT00647296 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 2 tablets taken orally twice daily
Study NCT00647296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo: 2 tablets taken orally twice daily
Study NCT00647296 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexpramipexole 50 mg/day
Description: Dexpramipexole: 2 x 12.5 mg tablets taken orally twice daily
Study NCT00647296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpramipexole 50 mg/day
Description: Dexpramipexole: 2 x 12.5 mg tablets taken orally twice daily
Study NCT00647296 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexpramipexole 150 mg/day
Description: Dexpramipexole: 2 x 37.5 mg tablets taken orally twice daily
Study NCT00647296 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexpramipexole 300 mg/day
Description: Dexpramipexole: 2 x 75 mg tablets taken orally twice daily
Study NCT00647296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpramipexole 300 mg/day
Description: Dexpramipexole: 2 x 75 mg tablets taken orally twice daily
Study NCT03140514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rejection treatment according to clinical standard-of-care
Description: Standard-of-care treatment is based on the severity and phenotype of biopsy-proven rejection
Study NCT01548547 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simulation-based mastery learning
Description: Hands-on coached deliberate practice on a simulator. Training until mastery achieved.
Study NCT01548547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation-based mastery learning
Description: Hands-on coached deliberate practice on a simulator. Training until mastery achieved.
Study NCT00798200 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise program
Description: All exercise programs will include endurance and strength exercises.
Study NCT02249416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir (TPV) low
Study NCT02249416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV) low
Description: Norvir®
Study NCT02249416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir (TPV) high
Description: Retrovir®
Study NCT02249416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV) high
Study NCT02249416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Study NCT01017185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HF10